1. Volume 74, Issue 1, Pages 124-128 (July 2018)
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma 
Sumanta K. Pal, Paulo Bergerot, Nazli Dizman, Cristiane Bergerot, Jacob Adashek, Russell Madison, Jon H. Chung, Siraj M. Ali, Jeremy O. Jones, Ravi Salgia 
European Urology 
Volume 74, Issue 1, Pages (July 2018)
DOI: /j.eururo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Pathology and radiographic findings for patients 1–3 with mPRCC with EML4-ALK rearrangement. mPRCC=metastatic papillary renal cell carcinoma.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Trend in tumor burden (based on the sum of longest dimension of index lesions) and associated systemic therapies rendered for (A) patient 1, (B) patient 2, and (C) patient 3 with mPRCC with EML4-ALK rearrangement. mPRCC=metastatic papillary renal cell carcinoma; PD=progressive disease; PR=partial response; SD=stable disease.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

4. European Urology 2018 74, 124-128DOI: (10.1016/j.eururo.2018.03.032)
Copyright © 2018 European Association of Urology Terms and Conditions